Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: Involvement of the insulin like growth factor-1 receptor

Prostate

Volumn 70, Issue 8, 2010, Pages 856-865

  Thomas, Francis ^a,b   Holly, Jeff M P ^a   Persad, Raj ^b   Bahl, Amit ^c   Perks, Claire M ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

1 integrin; Fibronectin; Insulin like growth factor 1; MKP 1; Prostate cancer

Indexed keywords

BETA1 INTEGRIN; CERAMIDE; DOCETAXEL; FIBRONECTIN; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RECEPTOR FOR ACTIVATED C KINASE 1; SOMATOMEDIN C RECEPTOR; TRYPAN BLUE; VITRONECTIN; ANTINEOPLASTIC AGENT; INTEGRIN; RADIOSENSITIZING AGENT; TAXOID;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; WESTERN BLOTTING; ANALYSIS OF VARIANCE; CELL COUNT; CELL CULTURE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PROSTATE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DUAL SPECIFICITY PHOSPHATASE 1; FIBRONECTINS; HUMANS; INTEGRINS; LAMININ; MALE; PROSTATE; RADIATION-SENSITIZING AGENTS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TAXOIDS; VITRONECTIN;

EID: 77952299924     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21119     Document Type: Article

References (44)

1. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, von Eschenbach AC. Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem Suppl 2004;16H:99-105.
2. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003;200:423-428.
3. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 1994;145:167-174.
4. Albrecht M, Renneberg H, Wennemuth G, Moschler O, Janssen M, Aumuller G, Konrad L. Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance. Histochem Cell Biol 1999;112:51-61.
5. Nagle RB. Role of the extracellular matrix in prostate carcinogenesis. J Cell Biochem 2004;91:36-40.
6. Skogseth H, Holt RU, Larsson E, Halgunset J. Tyrosine kinase inhibitors alter adhesivity of prostatic cancer cells to extracellular matrix components. APMIS 2006;114:225-233.
7. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997;33:263-271.
8. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59:1655-1664.
9. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-2483.
10. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-2923.
11. Cohen P, Rosenfeld RG. Physiologic and clinical relevance of the insulin-like growth factor binding proteins. Curr Opin Pediatr 1994;6:462-467. (Pubitemid 24245277)
12. Li W, Jiang YX, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang LH. Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol 1998;18:5888-5898.
13. Wang W, Kumar P, Wang W, Epstein J, Helman L, Moore JV, Kumar S. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998;58:4426-4433.
14. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003;23:3825-3835.
15. Meinbach DS, Lokeshwar BL. Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence? Urol Oncol 2006;24:294-306.
16. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-3994.
17. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-471, W83-W88.
18. Liliental J, Chang DD. Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit. J Biol Chem 1998; 273:2379-2383.
19. Cox EA, Bennin D, Doan AT, O'Toole T, Huttenlocher A. RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. Mol Biol Cell 2003; 14:658-669.
20. Kiely PA, O'Gorman D, Luong K, Ron D, O'Connor R. Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration. Mol Cell Biol 2006;26:4041-4051.
21. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE, Perks CM. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 2006;147:3484-3500.
22. Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TL, Visakorpi T. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer 2005;117:738-745.
23. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996;149:1553-1564.
24. Kiely PA, Baillie GS, Lynch MJ, Houslay MD, O'Connor R. Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration. J Biol Chem 2008; 283:22952-22961.
25. Kim F, Corson MA. Adhesion to fibronectin enhances MKP-1 activation in human endothelial cells. Biochem Biophys Res Commun 2000;273:539-545.
26. Schurko B, Oh WK. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 2008;5:506-507.
27. Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008;20:891-896.
28. Mendenhall WM, Henderson RH, Mendenhall NP. Definitive radiotherapy for prostate cancer. Am J Clin Oncol 2008;31:496-503.
29. Ganswindt U, Belka C. Radiotherapy in prostate cancer. Urologe A 2008;47:1245-1255.
30. Arya M, Shergill IS, Grange P, Emberton M. Hormone therapy:A revolution in understanding prostate cancer. Lancet Oncol 2008; 9:1112.
31. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
32. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. World J Urol 2005;23:10-13.
33. Petrylak DP. Clinical trials in metastatic hormone-refractory prostate cancer: Improving docetaxel therapy by targeting bone-related growth factors. Curr Oncol Rep 2007;9:211-212.
34. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 2003;278:50402-50411.
35. Sung SY, Chung LW. Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-521.
36. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993;119:637-644.
37. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159-170.
38. Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, Languino LR. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 2005;65:6692-6700.
39. Simon EL, Goel HL, Teider N, Wang T, Languino LR, Fitzgerald TJ. High dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and beta(1) integrin expression. Prostate 2005;64:83-91.
40. Srikanth S, Franklin CC, Duke RC, Kraft RS. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999;199:169-178.
41. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 2006;5:3122-3129.
42. Schmidmaier R, Baumann P. Anti-adhesion evolves to a promising therapeutic concept in oncology. Curr Med Chem 2008;15:978-990.
43. Sato M, Arap W, Pasqualini R. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park) 2007;21:1346-1352, discussion 54-55, 67, 70 passim.
44. Demirgoz D, Garg A, Kokkoli E. PR-b-targeted PEGylated liposomes for prostate cancer therapy. Langmuir 2008;24:13518-13524.